Pomeroy 1986.

Study characteristics
Methods	Randomised, double‐blind parallel group trial
Participants	38 people (23 men/15 women) aged 21‐66 years (median = 42 years) Tumour types: ovarian cancer (11 people), testicular cancer (9 people), bronchus carcinoma (8 people), non‐Hodgkin's lymphoma (3 people), Hodgkin's disease (2 people), sarcoma (2 people), breast cancer (1 person), melanoma (1 person), nephroblastoma (1 person) Chemotherapy regimens: cisplatin (10 people); cisplatin and treosulphan (7 people); cisplatin, vincristine, methotrexate and bleomycin (4 people), cisplatin, actinomycin D and etoposide (2 people); cisplatin, vinblastine and bleomycin (2 people); cisplatin and vindesine (1 person); adriamycin, bleomycin, vincristine and DTIC (2 people); adriamycin, vincristine and cyclophosphamide (2 people); adriamycin, vincristine, cyclophosphamide and prednisone (2 people); adriamycin, vincristine and etoposide (1 person); ifosfamide (2 people); vincristine, methotrexate and 5‐fluorouracil (1 person); vindesine, DTIC and 1‐(2‐chloroethyl)3‐cyclohexyl‐1‐nitrosurea (CCNU) (1 person). No information on doses reported Chemotherapy emetogenicity: high
Interventions	Nabilone 1 mg 3 times daily x 2 cycles orally, n = 19 Domperidone 20 mg 3 times daily x 2 cycles orally, n = 19
Outcomes	Episodes of vomiting daily, withdrawal due to adverse effects, lack of efficacy, episodes of drowsiness, dizziness, hypotension, euphoria
Notes	2 cycles of chemotherapy evaluated
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	Low risk	32/38 (84%) participants received nabilone, 33/38 (87%) participants received domperidone
Selective reporting (reporting bias)	Low risk	Data reported for primary outcome
Other bias	Unclear risk	Unclear if groups were balanced at baseline
Blinding of participants and personnel (performance bias) All outcomes	Low risk	"Identical capsules used"
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinding assumed as study reported as "double‐blind" and "identical capsules used"